Trials are stalled due to COVID-19. They don’t have to be.
Our Precedent for the Unprecedented
studies involving virtual assessments and digital technologies (wearable sensors, smartphone applications, radio frequency monitoring) since 2013
research participants in these studies, which have shown these approaches to be feasible, effective, and well-liked
We are currently conducting several virtual trials, including a longitudinal study tracking a cohort of LRRK2-carriers at increased risk for Parkinson’s disease (VALOR-PD) and a fully remote longitudinal follow-up study with participants from two Phase III clinical trials (AT-HOME PD).
Our Team Approach
As described in our brochure, CHeT houses a 50-person academic CRO that has conducted over 100 clinical trials involving 40,000+ participants that have led to 7 FDA-approved drugs, including four for Parkinson’s. We also have a drug packaging unit, a data analytics team, and an outcomes group that has developed FDA-accepted PROs for many neurological disorders.
The COVID-19 pandemic has shut down almost all site-based clinical trials. The resumption of such studies and the initiation of new ones will be challenging given the uncertainties surrounding the novel coronavirus. We can help.
Let’s stop being reactive and start being proactive. Let’s end the pauses, move forward, and create the future of clinical trials together.
Let's Get Started View More Resources